489 related articles for article (PubMed ID: 30247518)
1. Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions.
Yan YF; Zheng YF; Ming PP; Deng XX; Ge W; Wu YG
Brief Funct Genomics; 2019 Mar; 18(2):147-156. PubMed ID: 30247518
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
3. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Lim SW; Ahn MJ
Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
Memon H; Patel BM
Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
6. Targeting immune checkpoints in non small cell lung cancer.
Bianco A; Malapelle U; Rocco D; Perrotta F; Mazzarella G
Curr Opin Pharmacol; 2018 Jun; 40():46-50. PubMed ID: 29525401
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
8. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
[TBL] [Abstract][Full Text] [Related]
9. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
Schulz C; Gandara D; Berardo CG; Rosenthal R; Foo J; Morel C; Ballinger M; Watkins C; Chu P
Clin Lung Cancer; 2019 Nov; 20(6):451-460.e5. PubMed ID: 31375454
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
14. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in lung cancer: past, present and future.
Seetharamu N; Budman DR; Sullivan KM
Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Tan PS; Aguiar P; Haaland B; Lopes G
Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
[TBL] [Abstract][Full Text] [Related]
19. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
20. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
Lu S; Yu Y; Yang Y
Oncologist; 2019 Feb; 24(Suppl 1):S21-S30. PubMed ID: 30819828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]